Effects of low-energy shockwave therapy on the erectile function and tissue of a diabetic rat model.
Xuefeng Qiu, Guiting Lin, Zhongcheng Xin...
https://pubmed.ncbi.nlm.nih.gov/23253086/Actively Recruiting
Led by University of California, San Francisco · Updated on 2026-05-18
157
Participants Needed
1
Research Sites
N/A
Total Duration
This research evaluates the use of low-intensity shockwave therapy LI-SWT as a treatment for men with erectile dysfunction ED, a condition where it is difficult to achieve or maintain an erection firm enough for sex. The study aims to gather information on which patients benefit from this therapy to better predict outcomes and help guide treatment decisions. The device used has FDA clearance but is not yet approved specifically for ED treatment. Participants will receive six weekly sessions of LI-SWT using the UroGold100 device, which applies shockwave energy to the penis and perineum. Before treatment, patients complete questionnaires, blood tests, and a non-invasive blood vessel function test with the EndoPAT device. Follow-up visits occur at 3, 6, and 12 months after the initial baseline visit, including additional questionnaires and safety surveys. During the study, researchers will monitor erectile function using the International Index of Erectile Dysfunction-Erectile Function Domain IIEF-EFD score, focusing on changes three months after treatment and durability of improvement at six and twelve months. Safety and any adverse effects will be assessed throughout. Total study participation includes baseline assessments, treatment sessions, and follow-up evaluations over one year.
CONDITIONS
A Single Arm Study of Extracorporeal Shockwave Therapy for Management of Erectile Dysfunction
K
Karina Acevedo, Clinical Research Coordinator
J
Jennette Sison, MPH
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of California, San Francisco
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Shockwave therapy device | Standard oral medication for ED |
|---|---|---|
| What is it? | Extracorporeal shockwave therapy delivered via the UroGold100™ device, aiming to improve erectile function in men with ED. | Oral phosphodiesterase type 5 (PDE5) inhibitors, such as sildenafil, used as first-line medication to treat erectile dysfunction. |
| Primary use | Investigational device therapy intended to restore or improve erectile function for men with ED not treated with a penile prosthesis. | Accepted oral medication used to help patients achieve and maintain erections in daily life. |
| How is it given or performed? | Shockwave therapy sessions are performed using the UroGold100™ device, delivering acoustic pulses directly to penile tissue. | Patients take oral tablets such as sildenafil before planned sexual activity, per dosing instructions. |
| Evidence status | Shockwave therapy is under investigation. Meta-analyses of shockwave devices show moderate improvement in ED symptoms, but long-term efficacy is not fully established. | PDE5 inhibitors have strong published efficacy, with many patients experiencing improved erectile function and daily performance. Effect size is well documented. |
| Important limitations | Shockwave therapy lacks long-term outcomes and published registry data for the specific device; results may vary, and durability of improvement is uncertain. | Some patients cannot tolerate or do not respond to PDE5 inhibitors. Medication requires timing and can cause side effects. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit (in-person)
Duration - 6 weeks
Participants receive a series of 6 shockwave therapy sessions administered once a week for 6 weeks to the penis and perineum.
6 weekly visits (in-person) for therapy sessions with brief surveys between sessions
Duration - 12 months
Participants complete questionnaires and have assessments to monitor erectile function and any adverse reactions at 3, 6, and 12 months after the initial baseline visit.
3 visits at 3, 6, and 12 months (in-person or remote)
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Xuefeng Qiu, Guiting Lin, Zhongcheng Xin...
https://pubmed.ncbi.nlm.nih.gov/23253086/Jeffrey D Campbell, Bruce J Trock, Adam R Oppenheim...
https://pubmed.ncbi.nlm.nih.gov/30956690/Thomas Hausner, Krisztián Pajer, Gabriel Halat...
https://pubmed.ncbi.nlm.nih.gov/22575596/I Sokolakis, F Dimitriadis, D Psalla...
https://pubmed.ncbi.nlm.nih.gov/30120384/Guiting Lin, Amanda B Reed-Maldonado, Bohan Wang...
https://pubmed.ncbi.nlm.nih.gov/28258952/Seung Hwan Jeon, Kshitiz Raj Shrestha, Richard Y Kim...
https://pubmed.ncbi.nlm.nih.gov/26522972/Hongen Lei, Hua Xin, Ruili Guan...
https://pubmed.ncbi.nlm.nih.gov/26383610/Yur-Ren Kuo, Chun-Ting Wang, Feng-Sheng Wang...
https://pubmed.ncbi.nlm.nih.gov/19614917/Yuzuru Abe, Kenta Ito, Kiyotaka Hao...
https://pubmed.ncbi.nlm.nih.gov/25274132/Huibao Yao, Xiaofeng Wang, Hongquan Liu...
https://pubmed.ncbi.nlm.nih.gov/35319291/University of California, San Francisco
Lead Sponsor